Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
PLoS One ; 19(5): e0303080, 2024.
Article in English | MEDLINE | ID: mdl-38722876

ABSTRACT

Cricket Frass Fertilizer (CFF) was tested for its efficiency and potential as a fertilizer on the growth of green beans (Phaseolus vulgaris L.) in central Madagascar from April 2020 to October 2020. We grew green beans experimentally for 93 days with seven different fertilizer treatments: NPK 200 kg/ha (0.47 g of N/plant), GUANOMAD (guano from bat) 300 kg/ha (0.26 g of N/ plant), CFF 100 kg/ha (0.12 g of N/plant), CFF 200 kg/ha (0.24 g of N/plant), CFF 300 kg/ha (0.38 g of N/plant), CFF 400 kg/ha (0.52 g of N/plant), and no fertilizer (0 g of N/plant). Three plant traits were measured: survival proportion, vegetative biomass, and pod biomass. The survival proportion of plants treated with the highest dose of CFF (400 kg/ha, 88.1%), NPK (79.8%), and GUANOMAD (81.2%) were similar, but plants treated with the former yielded significantly higher vegetative (35.5 g/plant) and pod biomass (11 g/plant). These results suggest that fertilizing green beans with CFF at a 400 kg/ha dose is sufficient for plant survival and growth, and improves pod production. In Madagascar where soil quality is poor, dependence on imported chemical fertilizers (NPK) and other organic fertilizer (GUANOMAD) can be reduced. Cricket Frass Fertilizer can be used as an alternative sustainable fertilizer for beans.


Subject(s)
Fertilizers , Phaseolus , Fertilizers/analysis , Phaseolus/growth & development , Phaseolus/drug effects , Biomass , Madagascar , Animals , Gryllidae/growth & development
2.
Med Trop Sante Int ; 1(3)2021 09 30.
Article in French | MEDLINE | ID: mdl-35686164

ABSTRACT

Objective: Our work aimed to assess the efficacy and safety of direct-acting antiviral drugs in the treatment of hepatitis C in Madagascar. Methods: This retrospective clinical study was carried out from March 2018 to February 2020 in the hepato-gastro-enterology department of the University Hospital Center Joseph Raseta de Befelatanana. Results: A total of 35 patients were included, out of which 24 received sofosbuvir/ledipasvir ± ribavirin, 10 sofosbuvir/ribavirin and one sofosbuvir/velpatasvir. Thirty-three patients were naïve to the treatment and 2 patients were initially treated with the sofosbuvir/ledipasvir combination. The sustained virologic response was 94% (33/35) in the general population, 23/25 in cirrhotic patients and 10/10 in non-cirrhotic patients. The sustained virologic response was 22/24 for sofosbuvir/ledipasvir ± ribavirin, 10/10 for sofosbuvir/ribavirin and 1/1 for sofosbuvir/velpatasvir. Adverse effects were observed in 13 patients, mainly asthenia and insomnia. Discussion: The small number of patients with hepatitis C treatments and their limited financial resources are the main limits of this survey. Conclusion: Direct-acting antivirals are effective and characterized by good tolerance in these Malagasy hepatitis C patients.


Subject(s)
Hepatitis C, Chronic , Hepatitis C , Antiviral Agents/adverse effects , Drug Therapy, Combination , Genotype , Hepacivirus , Hepatitis C/drug therapy , Hepatitis C, Chronic/drug therapy , Hospitals, Teaching , Humans , Madagascar/epidemiology , Retrospective Studies , Ribavirin/therapeutic use , Sofosbuvir/adverse effects
3.
Int J Infect Dis ; 69: 20-25, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29408360

ABSTRACT

OBJECTIVE: To evaluate the feasibility of the implementation of a commercial rapid molecular diagnostic test (Xpert MTB/RIF) for the routine diagnosis of smear-negative or extrapulmonary tuberculosis (TB) and its diagnostic accuracy, and to assess HIV prevalence in a real-life setting in Madagascar. This study was set in a tertiary care hospital in Madagascar. METHODS: A prospective cohort study was conducted of all consecutive cases with suspected smear-negative and/or extrapulmonary TB over a 2-year period. Cases were classified as proven, probable, or possible TB cases, or as having an alternative diagnosis. RESULTS: Of the 363 patients included, 183 (50.4%) had suspected smear-negative pulmonary TB and 180 (49.6%) had suspected extrapulmonary TB. For proven cases, the sensitivity, specificity, positive and negative predictive values of Xpert MTB/RIF were 82.4%, 98.8%, 98.3%, and 86.6%, respectively; for proven and probable cases grouped together, these values were 65%, 98.8%, 98.5%, and 64%, respectively. The diagnostic accuracy was slightly lower for extrapulmonary TB compared to smear-negative pulmonary TB. The prevalence of HIV infection was 12.1%, but almost half of these cases did not have TB (alternative diagnosis group). CONCLUSIONS: The implementation of a rapid diagnosis programme for TB in a resource-poor setting is feasible. The performance of the Xpert-MTB/RIF was remarkable in this difficult-to-diagnose population. HIV prevalence in this study was much higher than the prevalence reported in the general population in Madagascar, in patients with TB and patients with conditions other than TB.


Subject(s)
Antitubercular Agents/therapeutic use , Molecular Diagnostic Techniques , Sputum/microbiology , Tuberculosis, Pulmonary/microbiology , Adult , Feasibility Studies , Female , Humans , Madagascar , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/genetics , Prevalence , Prospective Studies , Rifampin/therapeutic use , Sensitivity and Specificity , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/genetics
4.
Med Sante Trop ; 25(4): 436-40, 2015.
Article in French | MEDLINE | ID: mdl-26742557

ABSTRACT

Acute cholangitis secondary to ascariasis is rare and occurs mainly in areas of high endemicity. The clinical presentation is non-specific, sometimes complicated by liver abscess. Abdominal ultrasound plays an important role in diagnosis and therapeutic surveillance. We report the case of a 35-year-old Malagasy woman with an acute cholangitis secondary to ascariasis and complicated by liver abscesses and its course to full recovery under medical treatment.


Subject(s)
Ascariasis/complications , Cholangitis/parasitology , Liver Abscess/complications , Acute Disease , Adult , Female , Humans
5.
Med Sante Trop ; 23(1): 108-9, 2013.
Article in French | MEDLINE | ID: mdl-23360589

ABSTRACT

Helicobacter pylori (H. pylori) resistance against antibiotics is a major challenge, particularly in developing countries. We report a case of H. pylori infection where eradication by two lines of treatment, one including metronidazole and the other clarithromycin, failed, and discuss the management of such a case in a tropical area. This 55-year-old man complained of epigastric pain dating back for three years. A stool antigen test for H. pylori was positive. First-line eradication therapy, which combined a proton pump inhibitor, amoxicillin and metronidazole, was unsuccessful, as was the second-line therapy, which replaced metronidazole by clarithromycin. Third-line treatment, which still included a proton pump inhibitor and amoxicillin but added levofloxacin was successful. A stool antigen test to verify eradication was finally negative. In developing countries, H. pylori eradication must be managed rationally. In particular, fluoroquinolones must be reserved for treatment failure. The stool antigen test appears to be a useful and economical alternative to the urea breath test for verifying eradication.


Subject(s)
Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori , Levofloxacin/therapeutic use , Proton Pump Inhibitors/therapeutic use , Anti-Infective Agents/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination , Humans , Male , Metronidazole/therapeutic use , Middle Aged , Treatment Failure , Tropical Medicine
6.
Med Trop (Mars) ; 71(3): 305-7, 2011 Jun.
Article in French | MEDLINE | ID: mdl-21870565

ABSTRACT

Pernicious anemia is uncommon in Africa. The purpose of this report is to describe a case of pernicious anemia observed in Madagascar. The revealing manifestation was encephalomyelitis with combined medullar sclerosis that responded favorably to vitamin B12 replacement therapy. Clinical symptoms included paresthesia associated with allodynia of all four extremities and with tetrapyramidal syndrome, medullar ataxia and minor cognitive disturbances ongoing for 5 months. Hemogram testing revealed macrocytic anemia. Serum cobalamin level was low. Anti-intrinsic factor antibody was detected. Spinal cord magnetic resonance imaging showed diffuse high-signal intensity along the posterior spinal cord extending from C1 to C4. Vitamin B12 replacement therapy led to full regression of clinical signs after six weeks. Association of central nervous system involvement with macrocytic anemia suggests vitamin B12 deficiency and pernicious anemia should be suspected. This disease can be considered as a curable form of myelitis in Africa and Madagascar.


Subject(s)
Anemia, Pernicious/diagnosis , Encephalomyelitis/etiology , Anemia, Pernicious/drug therapy , Encephalomyelitis/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Tropical Climate , Vitamin B 12/therapeutic use , Vitamins/therapeutic use
7.
Article in French | AIM (Africa) | ID: biblio-1269084

ABSTRACT

L'hepatite fulminante est definie par l'association de signes d'encephalopathie hepatique a une chute du taux de prothrombine inferieur a 50survenant moins de deux semaines apres l'apparition d'un ictere. Elle est grave et mortelle en absence de transplantation hepatique. Cependant; nous rapportons un cas d'hepatite fulminante d'evolution favorable sous traitement medical seul. Il s'agissait d'un cas secondaire a un traitement antituberculeux qui a ete arrete tout de suite et remplace par un lavement au lactulose des l'apparition des signes d'encephalopathie hepatique. L'evolution etait marque par un retour progressif de l'etat de conscience a la normale et une amelioration nette du bilan hepatique


Subject(s)
Antitubercular Agents , Case Reports , Hepatic Encephalopathy , Hepatitis
8.
Revue Médicale de Madagascar ; 1(3): 69-70, 2011.
Article in French | AIM (Africa) | ID: biblio-1269366

ABSTRACT

Le virus d'Epstein-Barr est responsable de la mononucleose infectieuse. Il peut induire la formation d'anticoagulants circulants sans qu'apparaissent obligatoirement des manifestations thrombotiques. Nous rapportons le cas d'un jeune patient hospitalise pour une thrombose portale revelee par des manifestations douloureuses abdominales. La recherche d'anticoagulant circulant de type lupique dans le sang etait positive. Le bilan de thrombophilie s'averait negative. Nous n'avons pas retrouve de cas similaire dans la litterature. Le role des anticoagulants circulants semble etre primordial dans la constitution de cette obstruction de la veine porte. Une infection virale peut etre a l'origine de manifestations thrombotiques intra-abdominales par le biais de l'action thrombogene des anticoagulants circulants in vivo


Subject(s)
Anticoagulants , Case Reports , Epstein-Barr Virus Infections , Venous Thrombosis
9.
Med Trop (Mars) ; 70(2): 163-5, 2010 Apr.
Article in French | MEDLINE | ID: mdl-20486353

ABSTRACT

OBJECTIVE: Cirrhotic patients have poorer life expectancy than the general population. The purpose of this study was to identify causes of death in a sample of cirrhotic patients from Madagascar. METHODS: A retrospective analytic and descriptive study was conducted on the files of cirrhotic inpatients admitted to the gastroenterology department of the Joseph Raseta Befelatanana University Hospital Center in Antananarivo, Madagascar from January 1, 2003 to June 30, 2007. RESULTS: The files of 117 patients were reviewed. Death occurred in 31 cases for a mortality rate of 26.5%. The main causes of death were disorders of consciousness (51.6%) and hypovolemic shock (25.8%). Jaundice, encephalopathy, and gastrointestinal bleeding were predictive factors for mortality. CONCLUSION: Cirrhotic patients in this study were hospitalized at a late stage of disease. Further prospective study in a larger sample will be needed to standardize the management protocol in Madagascar.


Subject(s)
Cause of Death , Liver Cirrhosis/mortality , Female , Fever , Gastrointestinal Hemorrhage/mortality , Hepatic Encephalopathy/mortality , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Madagascar/epidemiology , Male , Middle Aged
10.
Sante ; 20(1): 15-9, 2010.
Article in French | MEDLINE | ID: mdl-20350861

ABSTRACT

INTRODUCTION: Although they remain a neglected transmissible disease, affecting mainly people in poor countries, the combined forms of schistosomiasis are second only to malaria as a major parasitic disease. Although both urinary and intestinal schistosomiasis are endemic in Madagascar, this study focuses only on the intestinal forms. The symptoms may remain unnoticed or be ignored, for the seriousness of intestinal schistosomiasis is due mainly to its hepatosplenic complications. OBJECTIVES: To estimate the etiological fraction of Schistosoma mansoni involved in hepatomegaly (HM), splenomegaly (SM) and hepatosplenomegaly (HSM), with or without signs of portal hypertension (PHT). METHODS: This file-based retrospective study includes patients admitted to the University Hospital of Antananarivo, Madagascar, between January 2005 and July 2008, who presented with HM, SM, HSM and/or PHT. The case was attributed to schistosomiasis if blood serology, tested with ELISA, was positive for this parasite. The statistical analysis used three approaches: a cross-sectional approach, a longitudinal approach (retrospective cohort), and a "case-control" approach. RESULTS: Of 7308 admissions during this period, 269 (4%) were diagnosed with a hepatosplenic complication and were retained. The average age (+/- standard deviation) was 47.8 (+/- 16.4) years. HM accounted for 55.4% of cases, SM 18.9%, HTP 18.6% and HSM 18.6%. Serology was positive for schistosomiasis in 21.6% of cases. The sex ratio (men:women) for these cases was 1.9, and 67.3% of the patients were aged 30 years or older. The main schistosomiasis complications were SM (n=22) and HTP (n=22). The age group most affected depended on the specific complication: for HM, 28.6% of patients were aged between 40 and 49 years; for HSM, 57.1% were aged between 30 and 40 years. The prevalence of SM was lower in subjects between 50 and 59 years of age (4.5%) than the other complications. Patients with positive serology results were significantly younger than those with negative results, or whose serology was not checked (37.8 years vs. 50.5 years, p < 0.001). Stratification according to complication showed that the etiological fraction of schistosomiasis was 76% for patients with SM, 79% for HTP, 58% for HSM and 4.9% for HM. The retrospective cohort and the case-control analyses both showed that a history of dysentery and frequent contact with water were the main factors associated with complicated schistosomiasis. It is important to note that urban and rural residents had the same risk of developing schistosomiasis with complications (OR: 0.9 [0.4; 1.9]). CONCLUSION: This study showed that schistosomiasis infection is strongly associated with hepatosplenic pathologies. One of the shortcomings of the study is the absence of any analysis of the course and outcome in the study patients. Nevertheless, the course of oesophageal varices, SM or HSM in patients with HTP indicates that schistosomiasis was often fatal.


Subject(s)
Hepatomegaly/parasitology , Schistosomiasis mansoni/complications , Splenomegaly/parasitology , Adult , Animals , Cross-Sectional Studies , Dysentery/epidemiology , Female , Hepatomegaly/epidemiology , Humans , Hypertension, Portal/parasitology , Longitudinal Studies , Madagascar/epidemiology , Male , Middle Aged , Prevalence , Schistosoma mansoni , Schistosomiasis mansoni/epidemiology , Schistosomiasis mansoni/etiology , Splenomegaly/epidemiology
11.
Revue Tropicale de Chirurgie ; 3(2): 40-41, 2009.
Article in French | AIM (Africa) | ID: biblio-1269445

ABSTRACT

L'hemoperitoine spontane est defini par la presence de sang dans la cavite peritoneale en l'absence de tout traumatisme. Il s'agit d'un accident rare mais grave. Nous rapportons le cas d'une jeune femme de 28 ans; sous traitement anticoagulant oral; qui presentait une douleur abdominale aigue; une instabilite hemodynamique et une deglobulisation sans notion de traumatisme. Le traitement medical doit etre propose en premiere intention en cas d'hemoperitoine. La prevention reste la meilleure strategie dans la prise en charge des accidents des anticoagulants


Subject(s)
Anticoagulants/adverse effects , Case Reports , Hemoperitoneum
12.
Bull Soc Pathol Exot ; 100(1): 28-9, 2007 Feb.
Article in French | MEDLINE | ID: mdl-17402690

ABSTRACT

Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension. Schistosomiasis may be an aetiology of this syndrome, however, few cases have been reported. We describe the first cases of portopulmonary hypertension with schistosomiasis in Malagasy patients. There were 2 men aged of 18 and 20 from hyperendemic area of schistosomiasis in Madagascar Both had a history of repeated water contact. They presented a dyspnea associated with ascites and oedema. Clinical examination showed portal and pulmonary hypertension with right ventricular heart failure. Cardiac examination revealed a systolic murmur and splint of the second heart pulmonary Pulmonary hypertension was confirmed by cardiac ultrasonogaphy Serology of bilharzias was positive. Parasitological examination showed eggs of S. mansoni. The treatment based on salt-free diet, spironolactone and praziquantel led to a better evolution of symptoms (case 1). Symptoms of right heart failure remained for the second patient even though improvement was noted. In tropical countries, schistosomiasis may be one of the cause of portopulmonary hypertension and may appear in early age. Its treatment remains difficult as the drugs recommended are not affordable.


Subject(s)
Endemic Diseases , Hypertension, Portal/etiology , Hypertension, Pulmonary/etiology , Schistosomiasis mansoni/complications , Adolescent , Adult , Anthelmintics/therapeutic use , Ascites/etiology , Combined Modality Therapy , Diet, Sodium-Restricted , Dyspnea/etiology , Heart Failure/diet therapy , Heart Failure/drug therapy , Heart Failure/etiology , Humans , Hypertension, Portal/drug therapy , Hypertension, Pulmonary/drug therapy , Madagascar/epidemiology , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , Praziquantel/therapeutic use , Schistosomiasis mansoni/drug therapy , Spironolactone/therapeutic use
13.
Bull Soc Pathol Exot ; 100(1): 57-60, 2007 Feb.
Article in French | MEDLINE | ID: mdl-17402699

ABSTRACT

Helicobacter pylori is a worldwide infection. However very few data are actually available on H. pylori seroprevalence in the Malagasy population. We carried out a transversal study in a sample of persons who met the following criteria: older than 15 years old, presence in the medicine internal unit 2 (University Hospital Center of Antananarivo) during the period of the study whatever the reason. H. pylori infection was identified serologically by using ELISA (G.A.P IgG H. pylori ELISA, Bio-Rad, France). Several factors were evaluated including serological status, demographic information, the reason of the presence in the unit, factors influencing H. pylori infection: socio-economic status, siblings, promiscuity consumption of alcohol, use of tobacco, water source and history of gastroscopy. The presence of clinical symptoms, such as dyspepsia and abdominal pain, was determined. Forty-five men and 45 women were included (mean age: 41.8 +/- 3.4 years). The seroprevalence of H. pylori infection was 82%. H. pylori infection was higher in men than in women (p < 0.02). Promiscuity constituted the principal factor influencing H. pylori infection. The seroprevalence of the H. pylori infection appears to be comparable to the rate encountered in developing countries. Considering this high rate of the H. pylori infection, eradication of H. pylori should be commonly recommended when facing gastrointestinal pathologies potentially induced by H. pylori.


Subject(s)
Antibodies, Bacterial/blood , Helicobacter Infections/epidemiology , Helicobacter pylori/immunology , Adult , Aged , Aged, 80 and over , Alcohol Drinking/epidemiology , Antibodies, Bacterial/immunology , Cross-Sectional Studies , Family Characteristics , Female , Gastroscopy , Humans , Madagascar/epidemiology , Male , Middle Aged , Risk Factors , Salaries and Fringe Benefits , Seroepidemiologic Studies , Sexual Behavior , Smoking/epidemiology , Socioeconomic Factors
14.
Rev Med Interne ; 26(7): 545-8, 2005 Jul.
Article in French | MEDLINE | ID: mdl-15925431

ABSTRACT

Portal vein thrombosis (PVT) seems rare among HIV infected patients. Even though, the report of such cases is of great interest because it may help to determine the factors of occurrence. We describe cases of PVT in 4 HIV-infected men, aged 32 - 64. Two of them were co-infected with hepatitis C virus (HCV). The four patients had a history of disseminated mycobacterial infection (one case of tuberculosis, 3 cases of mycobacterium avium complex infection) with abdominal lymphadenitis. Despite HAART, their immunodeficiency was profound (CD4: 65 to 216/mm(3)). At the time of diagnosis, two patients were treated with protease-inhibitor containing regimen: indinavir (one case), ritonavir-saquinavir (one case). PVT was revealed by haematemesis (one case), abdominal pain (ome case), anasarca (2 cases). In three patients, the diagnosis of PVT was confirmed by imagery (echo-doppler or angio- RMI), and for the last patient, PVT was found during the transjugular intrahepatic portosystemic shunt setup. A low level of C protein was diagnosed in one case. Cirrhosis was not found in HIV-HCV co-infected patients. Two patients died early after diagnosis, one patient died 3 years after the onset of symptoms. Various factors may cause the development of a PVT in HIV infected patient. Serious immunodeficiency, opportunistic infections such as tuberculosis and mycobacterium avium complex related infection with abdominal lymphadenitis can further the development of PVT. Protease-inhibitor might have facilitated the process. Due to the severe prognosis of advanced cases, early evocation of diagnosis is needed.


Subject(s)
HIV Infections/complications , Portal Vein , Venous Thrombosis/complications , AIDS-Related Opportunistic Infections/microbiology , Adult , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , Fatal Outcome , HIV Infections/diagnosis , HIV Infections/drug therapy , Humans , Male , Middle Aged , Venous Thrombosis/diagnosis , Venous Thrombosis/therapy
15.
Rev Med Interne ; 26(4): 280-7, 2005 Apr.
Article in French | MEDLINE | ID: mdl-15820563

ABSTRACT

OBJECTIVE: To describe efficacy and safety in clinical practice of pegylated interferon plus ribavirin (INFpeg-Riba) in the treatment of hepatitis C viral infection (HCV) in HIV infected patients. METHODS: Monocentric retrospective study with inclusion of all patients who received at least once INFpeg-Riba before April 1st 2003. All patients were followed up to six months after the end of HCV therapy. RESULTS: Thirty two HIV-positive patients (23 men and 9 women) with chronic hepatitis C treated by INFpeg-Riba were included. The mean age was 43 years. Fourteen patients carried HCV genotype 2 or 3 (43 %) and 18 patients carried genotype 1 or 4 (57%). The Metavir score of fibrosis showed fibrosis F1 (N =3), F2 (N =14), F3 (N =7) and F4 - cirrhosis (N =8). Twenty six patients (81%) were naive for anti hepatitis C drugs. Thirty one per cent of patients were at AIDS stage and 84% were receiving antiretroviral drugs. The mean CD4 cell count was 469 /ml and the plasma RNA HIV was less than 50 copies /ml in 57% of the cases. Adverse events leading to reduction of dose of drugs occurred in 40% and adverse events leading to discontinuation treatment occurred in 12%. A decline of CD4 cell count <200 CD4/ml was observed in 15%. Clearance of HCV-RNA in end of treatment was seen in 46 % and sustained virological response in 34 %. The main predictors of sustained virological response were HCV genotype 2 or 3 (P =0.04) and plasma HIV RNA less than 50 copies/ml (P =0.001). The predictive value of good virological response of a CD4 cell count >350/ml before treatment was very near the statistical significancy (p =0.07). CONCLUSIONS: The efficacy of pegylated interferon plus ribavirin in HIV-HCV co-infected patients is disappointing mainly due to a poor tolerance. In addition to HCV genotype, plasma HIV RNA level and CD4 cell count were essential to predict INFpeg-Riba response and should be taken into account in the process leading to the initiation of such therapy in HIV-HCV co-infected patients.


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/drug therapy , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Ribavirin/therapeutic use , Adult , Antiviral Agents/adverse effects , Drug Therapy, Combination , Female , Follow-Up Studies , HIV Infections/complications , Hepatitis C/complications , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Male , Polyethylene Glycols , Recombinant Proteins , Retrospective Studies , Ribavirin/adverse effects
16.
Clin Infect Dis ; 35(10): 1231-7, 2002 Nov 15.
Article in English | MEDLINE | ID: mdl-12410483

ABSTRACT

We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients reported side effects attributed to nevirapine, and 21% discontinued treatment because of poor tolerance. Administration of antihistamines or corticosteroids at the initiation of treatment was not protective against adverse events (relative risk, 0.82; 95% confidence interval, 0.49-1.38). The proportion of patients with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) coinfection who had alanine aminotransferase levels of >100 IU/L increased from 19.4% at baseline to 42.9% at month 12 of follow-up (P=.02). We noticed a significant increase of the proportion of patients with total cholesterol levels of >5.5 mM (P=.02). We have shown that there is a high level of discontinuation of nevirapine therapy in clinical practice and that side effects were not prevented by administration of antihistamines or corticosteroids. Coinfection with HCV or HBV increased the risk of hepatotoxicity, which lead to the cautious use of nevirapine for such patients.


Subject(s)
Anti-HIV Agents/adverse effects , Nevirapine/adverse effects , Adult , Alanine Transaminase/drug effects , Alanine Transaminase/metabolism , Cholesterol/metabolism , Cohort Studies , Female , France , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/metabolism , HIV-1/drug effects , HIV-1/genetics , Humans , Male , Retrospective Studies , Syndrome
18.
Arch Inst Pasteur Madagascar ; 67(1-2): 53-6, 2001.
Article in French | MEDLINE | ID: mdl-12471750

ABSTRACT

Neurocysticercosis is the most frequent parasitosis of central nervous system in the world. Neurological manifestations are in relation with locations number and topography, inflammatory reactions level and state of development of the parasite. Epilepsy is the main revealing symptom. Among other neurological manifestations, chronic headache, focal neurological signs, ataxia, language and behaviour disorder are the most anecdotal. The authors report a case of neurocysticercosis in a 71-year-old man with dysarthria and memory problems. Suspected by computed tomography, diagnosis was confirmed by immunoserologic assays such as enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunoelectrotransfer blot assay (EITB). This later emphasized on active form of the cyst. Specific treatment used albendazole as antihelminthic drug. Clinical evolution was good: neuroimaging and immunoserology results were normal respectively 2 and 6 months after the drug therapy.


Subject(s)
Neurocysticercosis/diagnosis , Aged , Albendazole/therapeutic use , Anthelmintics/therapeutic use , Dysarthria/parasitology , Endemic Diseases , Enzyme-Linked Immunosorbent Assay , Epilepsy/parasitology , Humans , Immunoblotting , Madagascar/epidemiology , Male , Memory Disorders/parasitology , Neurocysticercosis/complications , Neurocysticercosis/drug therapy , Neurocysticercosis/epidemiology , Tomography, X-Ray Computed , Treatment Outcome
19.
20.
Rev Med Interne ; 21(7): 623-7, 2000 Jul.
Article in French | MEDLINE | ID: mdl-10942979

ABSTRACT

INTRODUCTION: Before the HIV infection era, plasmocyte tumor rarely occurred in patients younger than 40 years of age. Less frequent than lymphomas, the incidence of these blood diseases has however substantially increased in HIV-infected patients. In these patients, in addition to onset at earlier age, their clinical presentation is quite different and extramedullary plasmocytomas in unexpected locations are more common. EXEGESIS: We report the case of a 29-year-old HIV-infected female patient in whom were diagnosed occipital, parotidal, sphenoidal, epidural, and uterine plasmocytomas for which chemotherapy and subsequent radiotherapy were successful. The increase in the incidence of plasmocyte tumors in HIV-infected patients might be facilitated by Epstein Barr Virus (EBV) co-infection, HIV-related chronic antigenic stimulation, and secretion of interleukin 6 by infected lymphocytes. CONCLUSION: Plasmocyte tumors belong to neoplasia whose incidence is increased in HIV infection. Their currently poor diagnosis should be improved by highly active antiretroviral therapies allowing enhanced chemotherapy with possibility of autograft.


Subject(s)
Brain Neoplasms/diagnosis , Lymphoma, AIDS-Related/diagnosis , Multiple Myeloma/diagnosis , Parotid Neoplasms/diagnosis , Uterine Neoplasms/diagnosis , AIDS-Related Opportunistic Infections/drug therapy , Adult , Antifungal Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Candidiasis, Oral/drug therapy , Female , Fluconazole/therapeutic use , Humans , Lymphoma, AIDS-Related/drug therapy , Lymphoma, AIDS-Related/radiotherapy , Multiple Myeloma/complications , Multiple Myeloma/drug therapy , Multiple Myeloma/radiotherapy , Parotid Neoplasms/drug therapy , Parotid Neoplasms/radiotherapy , Uterine Neoplasms/drug therapy , Uterine Neoplasms/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...